BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE 3rd, Kaumaya PT. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology 2012;1:1004-16. [PMID: 23170249 DOI: 10.4161/onci.21057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74-88. [PMID: 23890065 DOI: 10.1016/j.immuni.2013.06.014] [Cited by in Crossref: 520] [Cited by in F6Publishing: 517] [Article Influence: 57.8] [Reference Citation Analysis]
2 André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 2014;11:413-31. [PMID: 24913374 DOI: 10.1038/nrclinonc.2014.89] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 22.8] [Reference Citation Analysis]
3 Shi S, Tao L, Song H, Chen L, Huang G. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice. APMIS 2014;122:380-91. [PMID: 24628659 DOI: 10.1111/apm.12235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Comba A, Almada LL, Tolosa EJ, Iguchi E, Marks DL, Vara Messler M, Silva R, Fernandez-Barrena MG, Enriquez-Hesles E, Vrabel AL, Botta B, Di Marcotulio L, Ellenrieder V, Eynard AR, Pasqualini ME, Fernandez-Zapico ME. Nuclear Factor of Activated T Cells-dependent Down-regulation of the Transcription Factor Glioma-associated Protein 1 (GLI1) Underlies the Growth Inhibitory Properties of Arachidonic Acid. J Biol Chem 2016;291:1933-47. [PMID: 26601952 DOI: 10.1074/jbc.M115.691972] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
5 Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
6 Tegnebratt T, Lu L, Eksborg S, Chireh A, Damberg P, Nikkhou-Aski S, Foukakis T, Rundqvist H, Holmin S, Kuiper RV, Samen E. Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer. EJNMMI Res 2018;8:25. [PMID: 29616369 DOI: 10.1186/s13550-018-0380-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013;2:e23803. [PMID: 23734328 DOI: 10.4161/onci.23803] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
8 Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 2017;8:74378-90. [PMID: 29088794 DOI: 10.18632/oncotarget.20102] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
10 Schnatbaum K, Schmoldt H, Daneschdar M, Plum LM, Jansong J, Zerweck J, Kühne Y, Masch A, Wenschuh H, Fiedler M, Türeci Ö, Sahin U, Reimer U. Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362. Biotechnology Journal 2014;9:545-54. [DOI: 10.1002/biot.201300456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Scharovsky OG, Rico MJ, Mainetti LE, Perroud HA, Rozados VR. Achievements and challenges in the use of metronomics for the treatment of breast cancer. Biochemical Pharmacology 2020;175:113909. [DOI: 10.1016/j.bcp.2020.113909] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8:961-987. [PMID: 22894670 DOI: 10.2217/fon.12.95] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
13 Kaumaya PT. Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. Immunotherapy 2013;5:1159-63. [PMID: 24188668 DOI: 10.2217/imt.13.128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
14 Gokhale AS, Satyanarayanajois S. Peptides and peptidomimetics as immunomodulators. Immunotherapy 2014;6:755-74. [PMID: 25186605 DOI: 10.2217/imt.14.37] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
15 Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology 2014;3:e956005. [PMID: 25941587 DOI: 10.4161/21624011.2014.956005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]